Arialys Therapeutics, Inc.

We are hiring! We are currently building out our team for our upcoming #clinicaltrial to advance our lead drug candidate, ART-5803, a unique precision medicine approach to treat neuropsychiatric disorders driven by autoimmunity.  If you are interested in applying breakthrough science to expand treatment options for patients, please see our #openpositions. ➡️ Senior Clinical Trial Manager or Associate Director, Clinical Operations ➡️ Senior Director Project Management ➡️ Clinical Trial Manager See more here: https://lnkd.in/ecEzZpyw #biotech #SanDiego #careers #openposition #nowhiring

In this PharmaVoice Biotech Spotlight, our CEO Peter Flynn shares more about the vision of the company, why it matters, the terrifying and rapid symptoms of #ANRE and how our lead therapeutic candidate to treat autoimmune psychosis is “elegantly simple.” Read the article here: https://lnkd.in/ebPnT8z3 #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #antiNMDAR #NMDA #encephalitis #immunology #drugdiscovery #drugdevelopment #pharma #neuropsychopharmacology #precisionpsychiatry #autoimmune #pyschosis

We are excited to welcome Peter Flynn, Ph.D., as President and Chief Executive Officer of Arialys Therapeutics, Inc.! Peter has more than 20 years of executive leadership experience in the biotech industry, from private start-ups to established publicly traded companies, scaling companies through key financings and pharma partnerships, advancing novel therapeutics from scientific breakthrough to the clinic, and commercializing FDA-approved medicines. He joins us as we advance our lead drug candidate, ART5803, into clinical study for the treatment of ANRE and autoimmune psychosis. In addition, Jay Lichter, Ph.D., Managing Partner of Avalon BioVentures and former President and CEO of Arialys, has been appointed Chair of the company’s Board of Directors. Read the release here: https://lnkd.in/g44kyQCD #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #antiNMDAR #ANRE #NMDA #encephalitis #immunology #drugdiscovery #drugdevelopment #pharma #neuropsychopharmacology #precisionpsychiatry

Changing minds about autoimmune encephalitis: Drug Discovery News delves into the complex presentation and treatment of anti-NMDA receptor encephalitis (ANRE) and the precision medicine antibody that we hope will provide a meaningful treatment option. Aparna Nathan does a great job describing the rare condition, which causes immune cells to attack a receptor on the surface of neurons, leading to an array of psychiatric symptoms such as headaches, hallucinations, mania, and memory loss. It's also a story about serendipity, cross-disciplinary collaboration between neurologists and immunologists, and the potential of an antibody-specific targeted treatment that might ultimately be applicable to a larger swath of the population. Read more about our mission to 'put out a fire in the brain' and our lead drug candidate ART5803: https://lnkd.in/gy_QTFPP #encephalitis #NMDA #neurology #immunology #drugdiscovery #drugdevelopment #pharma #neuropsychopharmacology #neuropsychiatry #ANRE

When we describe anti-NMDA receptor encephalitis (#antiNMDAR), we often point to the book (or movie), Brain on Fire. This particular form of #encephalitis is caused by antibodies that specifically target the NMDA receptor and we have an opportunity to develop a #precisionmedicine to improve the treatment of this #autoimmunedisease. Early recognition and treatment will be essential to saving lives and improving patient outcomes. So for #WorldEncephalitisDay, we are (re)watching the movie and sharing this resource from Cleveland Clinic which provides more info about this disease: https://lnkd.in/gWSB945F Find out more about World Encephalitis Day here: https://lnkd.in/gRfCB6cs

What is the connection between the immune system and psychiatric disorders?  What’s the investment landscape in neuroscience?  What are the next steps for Arialys?  Our CEO, Jay Lichter, answers these questions and more in this interview with Investment Reports. Read the Q&A here: https://lnkd.in/dt5Xfkhg   #neuroscience #venturecapital #financing #investing #precisionmedicine #autoimmunedisease #antiNMDAR #autoimmunity

We are thrilled to be featured on Surani Fernando’s new #podcast Raising Biotech that explores biotechs raising impressive funds to develop ambitious medical breakthroughs. She speaks with our CEO Jay Lichter and our CAB chair Marty Jefson about advancing the first precision medicine for NMDA receptor encephalitis (ANRE), a rare, potentially lethal, and poorly managed neurological disease. Find our episode here: https://lnkd.in/dMKRgv8A Also check out Surani’s note about why she started this podcast: https://lnkd.in/gddmeC2D

Arialys has been recognized as one of the most innovative startups of 2023! We were chosen for the #PM360InnovationsIssue for advancing new precision medicines for #autoimmune #neuropsychiatric disorders. Arialys was founded on the breakthrough understanding that immune cells—not only in the body’s periphery but especially in the brain—can produce autoantibodies that cause severe neurological and psychiatric diseases. We look forward to advancing our lead drug candidate, ART5803, into clinical trials next year for the treatment of anti-NMDA receptor encephalitis (ANRE) and autoimmune psychosis. Read more at PM360 Magazine: https://lnkd.in/gsKbt67N #precisionmedicine

Our mechanism of action detailed here by Biotech Animated. Thank you to Benjamin Denton and team for bringing our science to life.